COMPANY HISTORY
Company History
2011
The unique potential of MRG-001 was discovered initially in promoting liver regeneration and the induction of liver allograft acceptance. MRG-001 has since been tested in various other preclinical disease models with promising results.
2016-Present
The MedRegen leadership partnered with a premier CDMO and invested heavily in developing a subcutaneous formulation of MRG-001 and is working towards producing an oral formulation.
2016-Present
All research and development was conducted and the results were filed for patent protection leading to licensing deals with MedRegen for 5 patent families.
2020
The US FDA approved MedRegen’s IND application for a combined phase I/II trial with MRG-001 for targeting COVID-19 patients.
2021
MedRegen entered into clinical development and initiated its phase I trial with MRG-001 in the US in healthy volunteers and progressed to a multicenter international phase 2 trial in severely and critically ill COVID19 patients.